Drug Trial Radar · NCT06058013
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
430
Actual
Start
Dec 20, 2023
Primary completion
May 6, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Neumora Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Conditions
- Major Depressive Disorder
Interventions
NMRA-335140Drug
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
PlaceboDrug
Placebo will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreTime frame: Baseline and up to Week 6
Locations
74 sites in 4 countries. Site status is shown where the registry gives one.
Neumora Investigator Site
Encino, California
Neumora Investigator Site
Garden Grove, California
Neumora Investigator Site
Los Alamitos, California
Neumora Investigator Site
Newport Beach, California
Neumora Investigator Site
Orange, California
Neumora Investigator Site
Santa Ana, California
Neumora Investigator Site
Norwalk, Connecticut
Neumora Investigator Site
Bradenton, Florida
Neumora Investigator Site
Hollywood, Florida
Neumora Investigator Site
Homestead, Florida
Neumora Investigator Site
Lauderhill, Florida
Neumora Investigator Site
Maitland, Florida
Neumora Investigator Sites
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami Lakes, Florida
Neumora Investigator Site
Miami Lakes, Florida
Neumora Investigator Site
Orlando, Florida
Neumora Investigator Site
Orlando, Florida
Neumora Investigator Site
Orlando, Florida
Neumora Investigator Site
Pinellas Park, Florida
Neumora Investigator Site
Pompano Beach, Florida
Neumora Investigator Site
Tampa, Florida
Neumora Investigator Site#1
Tampa, Florida
Neumora Investigator Site
Tampa, Florida
Neumora Investigator Site
Atlanta, Georgia
Neumora Investigator Site
Atlanta, Georgia
Neumora Investigator Site
Atlanta, Georgia
Neumora Investigator Site
Marrero, Louisiana
Neumora Investigator Site
New Orleans, Louisiana
Neumora Investigator Site
Baltimore, Maryland
Neumora Investigator Site
Towson, Maryland
Neumora Investigator Site
Boston, Massachusetts
Neumora Investigator Site
Boston, Massachusetts
Neumora Investigator Site
Watertown, Massachusetts
Neumora Investigator Site
Mankato, Minnesota
Neumora Investigator Site
Princeton, New Jersey
Neumora Investigator Site
Toms River, New Jersey
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.